John Edwards, CEO of Drusolv Therapeutics, lays out the company’s plan to use statins as a treatment for intermediate AMD. The firm is based off a 23-patient proof-of-concept trial that suggested 40% of the patients taking oral atorvastatin (Lipitor) reported reduced drusen and improved mean visual acuity. Drusolv expects to sell the statin directly to ophthalmologists as Ocustatin, a branded generic. Ophthalmologists would sell directly to patients. The company’s next step is running a Phase II/III clinical trial.